PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1349490

Beta-adrenergic blocking agents: their current status.

B K Clark
View original source ↗Export metadata ↓

Abstract

Use of beta (beta)-adrenergic blocking agents began in the 1960s and has risen dramatically since then. Newer agents offer more actions and fewer side effects. Uses for the drugs continue to increase as their safety and efficacy become increasingly apparent. beta block, today, has widespread application in cardiovascular disease. In addition, these agents are used in the management of endocrine disorders, neurologic situations, psychiatric disorders, gastrointestinal problems, and sensory disorders. Many new beta blockers are still investigational, and some show even greater promise for therapeutic applications in the future.

Explore related subjects

Adrenergic beta-AntagonistsAdultAgedAgingCardiovascular DiseasesChildEndocrine System DiseasesHumansMental DisordersMigraine DisordersNervous System DiseasesRacial GroupsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B K Clark. 1992. Beta-adrenergic blocking agents: their current status.. https://doi.org/10.4037/15597768-1992-2016

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Beta-adrenergic blockers as cardioprotective agents.

The evidence supporting and describing cardioprotective effects of beta-adrenergic blocker treatment is surveyed. Details of the many studies that individually and collectively document the ability of long-term and acute beta-blocker therapy to reduce overall mortality, sudden cardiovascular death, and nonfatal reinfarction in patients surviving or experiencing a myocardial infarction are described. A discussion of the mechanisms by which beta blockers probably and theoretically achieve these benefits includes the suggestion that they may reduce plaque rupture, thus indirectly inhibiting thrombosis. It is also suggested that, in the future, further cardioprotective benefits may accrue to the use of beta blockers in conjunction with thrombolysis and of beta blockers with a duration of action sustained throughout a full 24 hours.

Adrenergic beta-Antagonists↗
PubMed1992

[Developments in the treatment of myocardial infarction in Switzerland 1986-1990: results of a population survey].

The Swiss cantons of Vaud and Fribourg participate in the international MONICA project (MONI-toring of trends and determinants in CArdiovascular disease). Within this context, drug therapies and procedures were recorded during two separate years (1986 and 1990) for all hospitalizations of men aged 25 to 64 with the diagnosis of myocardial infarction. The medical files were reviewed to classify this diagnosis as possible or definite on the basis of the symptoms, the ECG results and the enzymatic tests. The two study populations (n = 318 in 1986 and n = 332 in 1990) are comparable with respect to age, history of ischemic heart disease and initial care. In 1990, half of the patients arrived at hospital in less than 3 hours, the median time delay being 4 hours for those first attending a general practitioner and 2 hours for those transferred directly. The frequency of treatments between 1986 and 1990 is compared only for cases with a definite diagnosis of myocardial infarction (respectively n = 217 and n = 223). The proportion of patients given thrombolytic therapy rose from 9% to 44% (p < 0.005) and from 51% to 95% (p < 0.005) for those treated with antiplatelet drugs, whereas the proportion fell from 72% to 55% (p < 0.005) for calcium blockers and from 33% to 24% (p < 0.05) for inotropic drugs. The use of anticoagulants (in 98% of patients) and of beta blockers (in 57%) remained stable across time.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Antagonists↗